Eye Health News and Research

Latest Eye Health News and Research

Obama seeks to mollify Democrats on health overhaul plan, costs

President Barack Obama intensified his push for health care reform by lobbying small groups of Democratic lawmakers Thursday.

5 Mar 2010

Johnson & Johnson Consumer to introduce CYTOMIMIC Technology at 68th AAD meeting

Building on decades of research into how the body's electrical field affects skin regeneration, scientists at Johnson & Johnson Consumer Companies, Inc., have discovered how to harness the power of bioelectricity to help improve skin rejuvenation. The new innovation, called CYTOMIMIC™ Technology, is a proprietary, patented technology that combines essential minerals to deliver biological levels of electric signals similar to the skin's natural bioelectricity.

5 Mar 2010

Crowding essentially 'blends' nearby objects together and makes the world appear more regular

As you read this, you may notice that the word directly in front of you is clear, but all the surrounding words are hard to make out. For most people, this effect - known as 'crowding' - is not a problem. However, for the millions of people worldwide who have lost their central vision through eye disease such as macular degeneration, it can make everyday tasks such as reading or recognising friends a challenge.

5 Mar 2010

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

The rapidly growing field of nanotechnology and its future use in cosmetic products holds both enormous potential and potential concern for consumers. Currently, major cosmetic manufacturers have imposed a voluntary ban on the use of nanoparticles in products while they await a ruling from the Food and Drug Administration regarding the safety of this technology.

5 Mar 2010

Latest diagnostic tools play crucial role in aiding dermatologists to spot melanomas at earlier

According to estimates from the American Cancer Society, melanoma, the most serious form of skin cancer, was responsible for an estimated 8,650 deaths in the United States in 2009. Of growing concern among dermatologists is the fact that melanoma is now the most common form of cancer for young adults 25-29 years old and the second most common cancer in adolescents and young adults 15-29 years old.

5 Mar 2010

Natural Solutions offers information about thyroid disease and thyroid medications

Is your thyroid making you fat? Around 27 million Americans have thyroid disease — and almost half don't know it. Thyroid disease arises when the hormone-producing gland at the base of your throat goes out of whack, triggering weight fluctuation, tiredness, and emotional ups and downs, among other symptoms.

5 Mar 2010

Dermatologist addresses common parasitic infestations and latest treatment options at Academy Annual Meeting

If simply the thought of bedbugs, scabies and head lice makes you feel a little itchy, imagine how those affected by these common infestations feel when they learn what has been creeping around them and causing symptoms such as intense itching, red bite marks or irritated scalps.

5 Mar 2010

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.

4 Mar 2010

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

Gene therapy for LCA clears another hurdle: Study

Gene therapy for a severe inherited blindness, which produced dramatic improvements last year in 12 children and young adults who received the treatment in a clinical trial, has cleared another hurdle. The same research team that conducted the human trial now reports that a study in animals has shown that a second injection of genes into the opposite, previously untreated eye is safe and effective, with no signs of interference from unwanted immune reactions following the earlier injection.

4 Mar 2010

Study indicates ocular shingles may increase stroke risk

Having a shingles infection that affects the eyes may increase the risk of stroke, according to new research published in the March 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

4 Mar 2010

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Bristol-Myers Squibb Company and Allergan, Inc. today announced a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain.

3 Mar 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

Eye injuries in young children: Keep liquid detergent capsules out of reach

In this week's BMJ, senior eye doctors are warning people to keep liquid capsules for fabric detergents out of the reach of children after a wave of eye injuries in young children at their hospital.

3 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Harvard Professor urges medical community to use ultrasound for diagnosing acute female pelvic conditions

In a bold, eye-opening editorial in the March 2010 issue of the Journal of Ultrasound in Medicine, Harvard Professor, Beryl Benacerraf, MD, urges the medical community to use ultrasound instead of Computed Tomography (CT) as the first-line imaging test for better diagnosis capability in the evaluation of acute female pelvic and lower abdominal conditions.

3 Mar 2010

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

Sunridge International, announced today that China's State Food and Drug Administration, (SFDA), had approved the firm's Pneumatic Trabeculoplasty (PNT) treatment in China.

3 Mar 2010

Phase III study results of Merck's allergy immunotherapy tablet

In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo

3 Mar 2010

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company’s Marketing Authorization Application (MAA) for the company’s lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

3 Mar 2010

Eye Health News and Research

Latest Eye Health News and Research

Obama seeks to mollify Democrats on health overhaul plan, costs

Johnson & Johnson Consumer to introduce CYTOMIMIC Technology at 68th AAD meeting

Crowding essentially 'blends' nearby objects together and makes the world appear more regular

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

Latest diagnostic tools play crucial role in aiding dermatologists to spot melanomas at earlier

Natural Solutions offers information about thyroid disease and thyroid medications

Dermatologist addresses common parasitic infestations and latest treatment options at Academy Annual Meeting

BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Gene therapy for LCA clears another hurdle: Study

Study indicates ocular shingles may increase stroke risk

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Allergan celebrates 20th anniversary of BOTOX in Canada

Eye injuries in young children: Keep liquid detergent capsules out of reach

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Harvard Professor urges medical community to use ultrasound for diagnosing acute female pelvic conditions

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

Phase III study results of Merck's allergy immunotherapy tablet

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Genetics & Genomics - Second Edition eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in